Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Advertisement
Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Sandoz Accuses United Therapeutics Of Blocking Generic Remodulin

A Sandoz lawsuit has accused United Therapeutics of trying to illegally block sales of the first US generic version of Remodulin.

Legal Issues Generic Drugs

MS Pharma Acquires Genepharm In Expansion Push

MS Pharma, a leading generics company in the Middle East, has announced an agreement to acquire Greece-based Genepharm as part of an expansion drive into Europe and farther afield.

Deals Strategy

Rescue Plan For Debt-Laden Panacea Sees Shares Soar

Distressed asset fund India Resurgence Fund, run by Bain Capital and the Ajay Piramal group, has announced a $144m bailout for financially ailing Panacea Biotec.

Strategy Generic Drugs

Dr Reddy’s Acquires Portfolio Of 42 ANDAs To Spur Growth In US

Dr Reddy’s is expanding its portfolio by acquiring 42 ANDAs in the US as it seeks to develop its North American and emerging market operations.

Strategy Deals

Russia’s Generium Announces First Biosimilar Of Soliris

Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.

Biosimilars Russian Federation

India’s Intas Launches Trastuzumab At A 65% Discount

India’s Intas Pharmaceuticals will undercut domestic rivals by marketing its new biosimilar trastuzumab at a price 65% cheaper than the current market cost.

Launches Biosimilars
See All
Advertisement
UsernamePublicRestriction

Register